Verastem, Inc. (VSTM)
Chart Events
Performance Outlook
| Previous Close | 9.50 |
| Open | 9.56 |
| Bid | 9.53 x 1300 |
| Ask | 9.61 x 1000 |
| Day's Range | 9.30 - 9.68 |
| 52 Week Range | 3.48 - 15.12 |
| Volume | |
| Avg. Volume | 203,384 |
| Market Cap | 242.659M |
| Beta (5Y Monthly) | 0.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for VSTM
Related Research
- Verastem, Inc.Analyst Report: Incyte CorporationIncyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.RatingFair ValueEconomic Moat19 hours agoMorningstar
- Business Wire
Verastem Oncology to Participate in Upcoming Investor Conferences
BOSTON, September 05, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:
- Business Wire
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers
BOSTON, August 28, 2023--Verastem Oncology (Nasdaq: VSTM) (the "Company"), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company has entered into a discovery and development collaboration with GenFleet Therapeutics ("GenFleet") to advance three oncology discovery programs targeting RAS pathway-driven cancers.
- Business Wire
Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
BOSTON, August 08, 2023--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the second quarter ending June 30, 2023 and highlighted recent progress.
